Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
1.
Ann Intern Med ; 174(1): JC3, 2021 01.
Article in English | MEDLINE | ID: covidwho-1518748

ABSTRACT

SOURCE CITATION: RECOVERY Collaborative Group. Lopinavir-ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 2020;396:1345-52. 33031764.


Subject(s)
Antiviral Agents/therapeutic use , COVID-19 Drug Treatment , Hospitalization , Lopinavir/therapeutic use , Ritonavir/therapeutic use , Administration, Oral , Aged , Antiviral Agents/administration & dosage , COVID-19/mortality , Drug Combinations , Female , Humans , Lopinavir/administration & dosage , Male , Multicenter Studies as Topic , Randomized Controlled Trials as Topic , Ritonavir/administration & dosage , SARS-CoV-2 , United Kingdom
2.
Ann Intern Med ; 173(8): JC41, 2020 10 20.
Article in English | MEDLINE | ID: covidwho-881504

ABSTRACT

SOURCE CITATION: Boulware DR, Pullen MF, Bangdiwala AS, et al. A randomized trial of hydroxychloroquine as postexposure prophylaxis for COVID-19. N Engl J Med. 2020;383:517-25. 32492293.


Subject(s)
Coronavirus Infections , Hydroxychloroquine , Medical Futility , Pandemics , Pneumonia, Viral , Adult , Betacoronavirus , COVID-19 , Coronavirus Infections/drug therapy , Humans , Hydroxychloroquine/adverse effects , SARS-CoV-2 , COVID-19 Drug Treatment
SELECTION OF CITATIONS
SEARCH DETAIL